摘要
目的探讨恶性淋巴瘤患者血清癌胚抗原(CEA)、糖类抗原125(CA125)、乳酸脱氢酶(LDH)及β2微球蛋白(β2-MG)变化与肿瘤临床分期和预后的相关性研究。方法选择2015年1月至2018年1月收治的恶性淋巴瘤患者107例;另选择2015年1月至2018年1月健康体检者63例为对照组。所有研究对象抽取外周静脉血,分离血清标本,采用化学发光法测定CA125和CEA含量,采用速率法测定LDH含量,采用免疫透射比浊法测定β2-MG含量。结果恶性淋巴瘤组血清CEA、CA125、LDH及β2-MG水平高于对照组,差异有统计学意义(P<0.05);Ⅲ～Ⅳ期血清CEA、CA125、LDH及β2-MG水平高于Ⅰ～Ⅱ期,差异有统计学意义(P<0.05);存活组血清CEA、CA125、LDH及β2-MG水平低于死亡组,差异有统计学意义(P<0.05)。结论恶性淋巴瘤患者检测血清CEA、CA125、LDH及β2-MG水平可作为病情、分期及预后的重要评价手段,具有重要临床研究价值。
Objective To explore the correlation between serum carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125), l actate dehydrogenase (LDH),β2 microglobulin (β2MG) and the clinical stage as well as prognosis in patients with malignant lymphoma. Methods A total of 107 patients with malignant lymphoma, who were admitted and treated in our hospital from January 2015 to January 2018, were enrolled as observation group,and the other 60 healthy subjects who underwent physical examination at the same period were enrolled as control group. The peripheral blood was extracted from all the subjects to separate serum. Chemiluminescence was used to detect the contents of CA125 and CEA, and the velocity method and immunoturbidimetry were used to detect the contents of LDH and β2MG, respectively. Results The serum levels of CEA, CA125, LDH and β2MG in observation group were significantly higher than those in control group ( P <0.05). The serum levels of CEA, CA125, LDH and β2MG at stageⅢ~Ⅳwere significantly higher than those at stageⅠ~Ⅱ( P <0.05). Furthermore, the serum levels of CEA, CA125, LDH and β2MG of the patients in survival group were significantly lower than those in death group ( P <0.05). Conclusion The detection of serum levels of CEA, CA125, LDH and β2MG can be used to evaluate the condition, staging and prognosis, which is of great clinical value.
作者
柯金勇
汪玉芳
KE Jinyong;WANG Yufang(Department of Hematology,Central Hospital of E’dong Medical Treatment Group,Hubei,Huangshi 435000,China)
出处
《河北医药》
CAS
2019年第7期1068-1070,共3页
Hebei Medical Journal
基金
湖北省卫生计生科研基金资助项目(编号:WJ2015MB203)
关键词
恶性淋巴瘤
癌胚抗原
糖类抗原125
乳酸脱氢酶
Β2微球蛋白
肿瘤临床分期
预后
malignant lymphoma
carcinoembryonic antigen
carbohydrate antigen 125
lactate dehydrogenase
β2 microglobulin
tumor clinical staging
prognosis
